Capital Mining to drill test areas of high grade lithium assay results at Wolfhound

Published 24-MAR-2017 15:37 P.M.

|

1 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Capital Mining (ASX: CMY) announced on Friday that the next phase of exploration at its Wolfhound lithium project in the Republic of Ireland will start immediately with the program testing areas that delivered high-grade assay results during the first phase field program.

The Wolfhound project is located adjacent to International Lithium Corp’s (ILC) joint venture Avalonia lithium project with China’s largest lithium producer, Ganfeng Lithium. Management also noted today that due diligence on its recently announced prospective cobalt acquisition (Scotia cobalt nickel project located in Western Australia) is progressing well, with a market update imminent.

Confirmation of the acquisition of Scotia should be well received by investors given the sharp share price response as illustrated below when the purchase was flagged on March 9.

It should be noted that historical data in terms of earnings performance and/or share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.

Looking specifically at the Wolfhound project, CMY’s maiden exploration program was successful in identifying lithium bearing pegmatites at the priority Ballon and Borris prospects.

Assay results from the first phase field work included an outstanding high grade rock chip assay of 2.47% lithium dioxide at the Borris prospect.

Should the company be able to provide further assay results in the vicinity of 2%, it is likely that the Wolfhound project will attract the interest of investors looking for an early stage project in the lithium space.

tags

LITHIUM


General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X